Navigation

PRESS RELEASES

Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure

By AGT | Aug 3, 2020
Filed Under:

ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), an internationally recognized advanced gene and cell therapy company in Rockville, MD, today announced a coauthored article by scientists from AGT and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), regarding AGT’s promising cell and gene therapy for HIV. Through a collaboration… [Read More]

American Gene Technologies (AGT) Moves HQ to New Facility, Expands Lab Space for HIV and Cancer Cure Research – Across From National Cancer Institute Campus

By AGT | Jul 28, 2020
Filed Under:

ROCKVILLE, Md., July 28, 2020 — American Gene Technologies (AGT), an internationally recognized leading gene and cell therapy company in Rockville, Maryland, today announced it has leased a spacious, modern facility in the Maryland life sciences corridor, across from National Cancer Institute and Johns Hopkins Shady Grove Campus. Click on images to view larger The new facility will support AGT’s… [Read More]

American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston

By AGT | Mar 10, 2020
Filed Under:

ROCKVILLE, Md., March 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT), a leading gene and cell therapy company in Rockville, Maryland, is pleased to announce its Chief Science Officer C. David Pauza, Ph.D will present at the Inborn Errors of Metabolism Drug Development Summit in Boston, MA on March 11, 2020. Dr. Pauza will present how AGT used its proprietary, lentiviral… [Read More]

American Gene Technologies To Attend J.P. Morgan Healthcare Conference 2020

By AGT | Jan 8, 2020
Filed Under:

ROCKVILLE, MD, January 8, 2020 – American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the 38th annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 12-16 in San Francisco, California. American Gene Technologies’ second invitation to attend the conference follows its continued discussions with J.P. Morgan and other biotechnology investment… [Read More]

American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

By AGT | Nov 6, 2019
Filed Under:

Press release also featured on:  GlobeNewswire.com ROCKVILLE, MD, November 06, 2019 – American Gene Technologies (AGT) announced today it will host a red carpet event tonight to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy: AGT successfully submitted its Investigational New Drug (IND) application to the Food & Drug Administration (FDA) to… [Read More]

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

By AGT | Oct 18, 2019
Filed Under:

ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the disease. “Our aim is to treat HIV disease with an innovative cell and gene therapy… [Read More]

American Gene Technologies to Present at 2019 Cell & Gene Meeting on the Mesa

American Gene Technologies to Present at 2019 Cell & Gene Meeting on the Mesa

By AGT | Oct 2, 2019
Filed Under:

ROCKVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California. Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day… [Read More]

HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

By AGT | Jul 2, 2019
Filed Under:

ROCKVILLE, Md. — American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV positive individuals. AGT will use these materials to validate the… [Read More]

HIV Cure Program Patent Granted To American Gene Technologies

HIV Cure Program Patent Granted To American Gene Technologies

By AGT | May 21, 2019
Filed Under:

ROCKVILLE, Md., May 21, 2019 (GLOBE NEWSWIRE) — American Gene Technologies, a leading gene and cell therapy company based in Rockville, Md., was granted a second patent for its unique molecule, methods, and cell process for its HIV program. This patent further protects AGT’s lentiviral vector and proprietary process for generating autologous cell products to treat HIV (“HIV Pre-Immunization and Therapy” US 10,233,464). AGT’s… [Read More]

AGT Launches Oncology Science Advisory Group to Accelerate Research For A Cancer Cure

AGT Launches Oncology Science Advisory Group to Accelerate Research For A Cancer Cure

By AGT | Mar 25, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, March 25, 2019 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy biotech company based in Rockville, Md., has established an advisory group for the advancement of immunotherapies that activate gamma-delta (γδ) T cells to attack a variety of tumors including liver, prostate, and breast cancers. This is an initial step in AGT’s… [Read More]

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Mailchimp sidebar

Follow AGT on Social Media

Send this to a friend